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Abstract
Molecular  profiling  facilitates  the  under-
standing of the genetic processes underlying
the development of cancer, and makes it pos-
sible to use specific signatures to prognosti-
cate clinical outcome and to predict response
to specific treatments. There has been a great
increase  in  the  availability  of  tools  for  ex-
ploring genetic abnormalities in cancer cells,
which  have  allowed  a  more  comprehensive
characterization of the mutations, transloca-
tions, and copy-number variations that may af-
fect the development of cancer or therapy re-
sponse. An improved understanding of the mo-
lecular basis of cancer is helping also in the
identification  of  new  molecular  targets  for
therapy.
Introduction
A key aim in the management of cancer is
to associate the diagnosis to the treatment, so
that  treatments  are  more  effective  and  the
probability of curing patients is improved. For
this,  the  concept  of  molecular  cancer  tax-
onomy is essential – a system that allows cli-
nicians  to  assign  treatments  to  patients,
based  on  the  morphology/immunopheno-
type/molecular  features  of  the  disease.  Tax-
onomy requires the precise definition of clini-
copathologic entities and molecular markers
that are specific to each condition. This classi-
fication system leads to the identification of
underlying molecular alterations, targets for
therapy and predictive and prognostic markers
for patient stratification. 
The cancer sequence
Cancer molecular profiling has greatly fa-
cilitated  a  more  comprehensive  under-
standing of the processes underlying the de-
velopment of cancer cells. An early stage is
the presence of inherited plus acquired ge-
netic  mutations  and  epigenetic  changes  in
the cells, which at this stage are not yet neo-
plastic cells, but acquire a selective survival
advantage. Cancer cells then acquire the ca-
pacity for self-renewal, so-called stemness, al-
though it is not clear at this time whether all
cancer cells have this capacity or only a mi-
nority of them, or even whether this is just
transiently acquired. These cells develop into
a tumor when they get the capacity for local
infiltration, probably through development of
a  signature  identified  as  epithelial-mes-
enchymal  transition.  Eventually,  these  cells
gain the capacity for distant metastasis, re-
quiring  drug  treatment.  Finally,  during
therapy,  these  tumors  can  develop  genomic
instability, which allows them to escape the
therapy. The steps for this sequence are still a
matter of investigation, and new concepts and
data may dramatically change our current un-
derstanding of cancer.
Genetic sequencing of cancer cells
A key advance in our study of cancer has
come from the development of technology and
reduction  of  the  cost  of  gene  sequencing,
which has produced a great increase in the
amount of sequencing data that are starting to
be available.1 This has led to the formation of
the  International  Cancer  Genome  Consor-
tium. The goal of this consortium is to coordi-
nate the generation of comprehensive cata-
logs of genomic abnormalities (somatic muta-
tions)  in  tumors  from  50  different  cancer
types and/or subtypes that are of clinical, sci-
entific, or social importance across the globe.2
For  each  of  these  50  cancer  types/subtypes,
the objective of the consortium is to sequence
at least 500 cases. This project is ongoing, for
example  in  breast  cancer,  lymphoma,  and
other common types of cancer – some of the
tumor types have still to be defined. It is the
most ambitious project that has ever been de-
veloped in the field of biomedicine or cancer
research, as it encompasses the sequencing of
50,000 genomes. 
Multiple mutations in cancer cells 
An important finding discovered in recent
years is that most cancer samples have mul-
tiple somatic mutations, rather than the small
number that was originally expected. In that
context, it is not surprising that targeted ther-
apies that are directed at single mutations are
not fully effective. A study of tumor cells in
pancreatic cancer found that these tumors had
an average of 63 genetic alterations, the ma-
jority of which were point mutations, and some
cancers had more than 100 genetic alterations
(Figure  1).3 The  frequency  of  mutational
changes is nevertheless changing among dif-
ferent tumor types, with higher frequency in
tumors associated with smoking or exposure
to ultraviolet light, such as lung cancer and
melanoma.  The  mutations  characterized  in
pancreatic cancer are not distributed randomly
across the genome, but affect particular sig-
naling  pathways  and  processes  in  the  cells,
forming  a  complex  system  of  changes.  The
challenge for researchers, therefore, is now to
understand the data that are available on ge-
netic changes, and move on from that to dis-
cover the implications for targeted therapy of
the patients. 
Therapy driven by molecular 
diagnosis 
The concept we are now trying to sustain
and develop is phrased as therapy driven by
molecular diagnosis. Research strategies aim
to match the individual genetic variability of
tumor samples and patients with therapies ad-
justed to these variables. This will be achieved
through the combination of: early diagnosis for
screening of patients at risk; the definition of
prognostic markers that would allow us to as-
sign  individual  treatments  and  stratify  pa-
tients by their individual risk; and the develop-
ment of therapies for the newly identified ther-
apeutic targets. 
Tools for molecular diagnosis 
Analysis of the genomes of cancer patients
now  allows  the  characterization  of  several
types of genetic changes. These include point
mutations, insertion or deletion of sequences,
inter-  and  intrachromosomal  translocations,
and  copy-number  changes.4 These  somatic
mutations  can  be  examined  using  DNA  mi-
croarrays,  to  investigate  single-nucleotide
polymorphisms  (SNPs),  copy-number  varia-
tions,  and  gene-expression  signatures.
Changes in gene expression and protein prod-
ucts can also be measured using tissue im-
munohistochemical microarrays. In addition,
microRNA (miRNA) arrays are starting to be
used,  and  techniques  for  analyzing  miRNAs
have  been  applied  using  formalin-fixed,
paraffin-embedded tissue studied using quan-
titative polymerase chain reaction (QT-PCR)
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analysis  of  gene  polymorphisms  in  patients
and  copy-number  variation  in  tumors.  How-
ever,  interpretation  of  these  results  is  not
simple – millions of SNPs can be identified in
an  individual,  but  most  of  these  cannot  be
linked to specific risk for a disease, or to re-
sponse to therapy. In most cases, the impact of
an SNP is not individually important, although
in some cases it may produce a different gene
product or alter the regulation of a gene with
significant pathogenic results. 
The use of tissue microarrays has led to the
development of antibodies that can be used to
identify  specific  cancer  phenotypes.  For  ex-
ample, germinal center B-cell-expressed tran-
script 1  (GCET1)  has  been  used  to  charac-
terize B-cell lymphomas,5 and the expression
of B-lymphocyte-induced maturation protein-1
(BLIMP-1) has been found to constitute the
best  marker  of  plasma  cell  differentiation
among  normal  and  neoplastic  B-cells.6 Im-
munohistochemical  staining  in  tissue  mi-
croarrays can also be used to quantify the ex-
pression of key regulatory proteins (e.g. Bcl-2,
Lyn, Syk). These may be highly important in
the future because, by using such microarrays,
expression of multiple markers can be visual-
ized at the same time in a tumor sample. More-
over, as tumor cells are unstable and their ge-
netic  composition  changes  with  time,  this
technique should allow us to monitor differ-
ences  both  between  tumors  and  within  the
same tumor over time. 
Identifying molecular risk
Tumor specimens can be analyzed to iden-
tify  specific  molecular  risk  scores.  For  ex-
ample, in samples from patients with advanced
Hodgkin’s  lymphoma,  quantitative  reverse-
transcription PCR was applied to 30 genes to
develop  a  molecular  risk  score.7 There  are
likely to be hundreds of markers that affect pa-
tients’ molecular risk in this condition, but it is
not  feasible  to  work  with  large  numbers  of
markers, so they were reduced to a reasonable
number, to focus on the best predictors. These
were integrated into an 11-gene model, incor-
porating genes from four functional pathways:
the cell cycle, apoptosis, macrophage activa-
tion, and interferon regulatory factor 4. This
produced a single molecular risk score for indi-
vidual patients, which predicted response to
treatment and 5-year failure-free survival (de-
fined as the time interval between treatment
initiation and treatment failure or last follow-
up). Importantly, in this and other studies it
has been found that the molecular risk was in-
dependent of clinical risk. Thus, molecular and
clinical risk could be combined, and in this way
it was possible to identify about 25% of pa-
tients who were at very high risk of not re-
sponding to therapy, carrying a very unfavor-
able prognosis (Figure 2).7
Identifying treatment targets
Lamb et al. have reported their development
of  a  reference  database  of  gene-expression
profiles from cell lines. These can be mined for
connections with gene signatures of specific tu-
mors  or  experimental  conditions,  to  form  a
connectivity map that relates tumor signatures
with response to specific treatments.8 Multiple
practical applications of this approach have al-
ready been generated. For instance, an expres-
sion profile of genes thought to play a role in
the  pathogenesis  of  chronic  lymphocytic
leukemia revealed variability in the expression
of two gene clusters associated with B-cell-re-
ceptor signaling and mitogen-activated protein
kinase activation. Variations in the expression
of these two clusters identified three groups of
patients who had different risks of treatment-
free survival.9 Using such techniques, there-
fore, gene expression may be used to predict
patients’ treatment needs at early stages of the
disease. These potential drug sensitivities can
be tested in vitro using measurable pharmaco-
dynamic markers. In this way, the introduction
Figure 1. The number of genetic alterations detected through sequencing and copy-number
analyses in each of 24 pancreatic cancers.3 From Jones S et al. Core signaling pathways in
human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
Reprinted with permission from AAAS.
Figure 2. Integration of the molecular risk score and clinical risk (stage IV disease) identified
a quartile of patients with particularly poor prognosis.7 Refer to main text for definition of
failure-free survival. This research was originally published in Blood. Sanchez-Espiridion B
et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin
lymphoma. Blood 2010;116:e12-17.© The American Society of Hematology.
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of new therapies for hard-to-treat cancers may
be accelerated. 
A  second  tool  for  identifying  molecular
treatment  targets  is  gene  set  enrichment
analysis (GSEA) – a computational method
that determines whether an a priori-defined
set  of  genes  shows  statistically  significant
differences  between  two  phenotypes
(www.broad.mit.edu/gsea).  This  approach
has been used to screen a database of drug-
associated gene-expression profiles for mole-
cules  whose  profile  overlapped  with  the
gene-expression signature of glucocorticoid
sensitivity in acute lymphoblastic leukemia.
This indicated that the gene-expression pro-
file  of  the  mTOR  inhibitor  rapamycin
matched the signature of glucocorticoid sen-
sitivity. Further testing demonstrated that ra-
pamycin  could  induce  glucocorticoid  sensi-
tivity  in  neoplastic  lymphoid  cells.10 This
demonstrates how GSEA can be used to iden-
tify promising new or combination therapies.
Likewise, in cutaneous T-cell lymphoma, this
approach  demonstrated  that  the  histone
deacetylase  inhibitor  vorinostat  interfered
with the signal-transduction pathway of the
T-cell receptor, and synergized with phospho-
inositide-3 kinase inhibitors.11 Thus, the de-
velopment  of  new  drugs  and  combination
therapies  is  being  accelerated  through  the
use of molecular diagnostic techniques. 
Conclusions 
It may be possible to stratify patients for tar-
geted therapy using molecular diagnosis. This
approach requires clear, specific markers that
can be applied at diagnosis, and pharmacody-
namic markers to assess responses to treat-
ment. New drugs and combinations may also
be assayed in vitrousing these molecular tech-
niques.  Rapid  and  flexible  clinical  trials  are
needed to move ahead with the introduction of
new drugs developed in this way. 
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